1. Introduction {#s0005}
===============

Presence of diabetes was an independent factor associated with poor outcomes during the past coronavirus infections such as Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-COV-1) in 2003 [@b0005] and Middle-East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012 [@b0010]. Interestingly, acute diabetes was commonly observed finding during SARS-COV-1 in patients without prior history of diabetes and without using glucocorticoids, and was an independent predictor for mortality [@b0005]. This acute hyperglycemia was linked to binding of SARS-COV-1 to the angiotensin-converting enzyme 2 (ACE2) receptor present in pancreatic islets with resulting islet damage [@b0015]. It should be noted that knockout of ACE2 gene lead to an acute diabetes in experimental animal studies [@b0020].

While presence of diabetes has been frequently associated with severe Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), "new-onset" hyperglycemia with or without diabetes and acute metabolic decompensation of pre-existing diabetes associated with COVID-19 is also not an uncommonly recognized phenomenon. These findings hint to a bidirectional relationship between diabetes and COVID-19. An international group of leading diabetes researchers participating in the CoviDIAB Project, have established a global registry of patients with COVID-19-related diabetes [@b0025]. Nevertheless, emerging data increasingly suggests that "new-onset" hyperglycemia is a frequently observed finding especially in admitted patients with COVID-19, who had no history of dysglycemia or diabetes in the past and were currently not on corticosteroids. This entity of "new-onset" hyperglycemia could be classified as - a. "stress-induced" hyperglycemia, b. "new-onset diabetes" in previously unrecognized pre-diabetes, c. hyperglycemia possibly related to SARS-CoV-2 direct effect on pancreas and, d. drug-induced hyperglycemia or "secondary diabetes" during the course of treatment for COVID-19, especially with frequent use of corticosteroids.

American Diabetes Association (ADA) defines new-onset hyperglycemia without diabetes when fasting plasma glucose (FPG) is between 5.6 and 6.9 mmol/L (100--125 mg/dL) and/or HbA1c is between 5.7 and 6.4%, in absence of dysglycemia in past. Similarly, new-onset diabetes would be defined in presence of two abnormal samples either FPG is ≥ 7.0 mmol/L (≥126 mg/dL) or HbA1c ≥ 6.5% or a random glucose level ≥ 11.1 mmol/L (≥200 mg/dL) with symptoms of hyperglycemia, in absence of any history of diabetes in past [@b0030]. Since a stress response to an acute viral infection such as COVID-19 can unlikely impact the HbA1c but may increase the plasma glucose, thus a single FPG value of ≥ 7.0 mmol/L (≥126 mg/dL) in absence of HbA1c ≥ 6.5% has been labelled by researchers as new-onset hyperglycemia without diabetes. Intriguingly, while some studies have used the ADA criteria to define new-onset hyperglycemia with or without diabetes, few had overlapped value of FPG and HbA1c and others have used a completely different cut-off value to evaluate the outcomes in individuals with COVID-19.

Ceriello *et al.* [@b0035] and Apicella *et al.* [@b0040] have evaluated a possible pathogenic mechanism of new-onset hyperglycemia in patients with COVID-19. Authors have proposed insulin resistance and possibly insulin secretory defects, both might be at interplay in precipitating acute glycemia in patients with COVID-19, even in the absence of pre-existing diabetes. In this commentary, we sought to review and descriptively analyze the studies that evaluated the outcomes in patients with COVID-19 with "new-onset" hyperglycemia with or without diabetes.

1.1. Outcomes in patients with new-onset hyperglycemia without diabetes versus normoglycemic COVID-19 {#s0010}
-----------------------------------------------------------------------------------------------------

One of the first study by Bode *et al.* [@b0045] found that hyperglycemia in people with diabetes (HbA1c ≥ 6.5%) or, without diabetes (defined as two or more blood glucoses \> 180 mg/dL occurred within any 24-hour period with an HbA1C \< 6.5% or no HbA1C testing done during hospitalization) was significantly associated with an increase in mortality with COVID-19, compared to people with normoglycemia (28.8% vs. 6.2% respectively; p \< 0.001). Zhang *et al.* [@b0050] reported a significant increase (Odds ratio \[OR\] 5.47; 95% confidence interval \[CI\], 1.51--19.82; p = 0.010) in composite outcomes risk (mechanical ventilation \[MV\], admission in intensive care unit \[ICU\] and death) in people with secondary hyperglycemia and COVID-19 (defined as FPG ≥ 7.0 mmol/L \[≥126 mg/dL\] but HbA1c \< 6.5%), compared to the patients with normoglycemia. Sardu *et al.* [@b0055] showed a 71% relative increase in mortality (Hazard ratio \[HR\] 0.29; 95% CI, 0.08--0.96; p = 0.04) from severe COVID-19 in individuals with at-admission hyperglycemia (new-onset hyperglycemia without diabetes or pre-existing diabetes, with a plasma glucose \> 7.77 mmol/l \[\>140 mg/dL\]), compared to normoglycemic individuals with or without diabetes, through 18 days. The Kaplan-Meier (KM) survival analysis also found significantly less (p \< 0.02) numbers of patients with hyperglycemia (with or without diabetes) were free from severe COVID-19, compared to individuals with normoglycemia.

Similarly, Wang *et al.* [@b0060] found a significantly increased 28-day in-hospital complications (OR 2.61; 95% CI, 1.64--4.41) in patients with COVID-19 with hyperglycemia without diabetes (FBG 6.1--6.9 mmol/L), compared with normoglycemic individuals. While Li *et al.* [@b0065] demonstrated an increase trend in all-cause mortality (HR 3.29; 95% CI, 0.65--16.6) in patients with hyperglycemia without diabetes (FPG 5.6--6.9 mmol/L and/or HbA1c 5.7--6.4%), compared to normoglycemic patients (FPG \< 5.6 mmol/L and HbA1c \< 5.7%) with COVID-19, at a mean follow-up of 30 days. The most recent study by Coppelli and colleagues reported that mortality was significantly higher in hyperglycemia without diabetes (defined as no diabetes and glucose ≥ 7.78 mmol/L at admission) compared with normoglycemic patients (at-admission blood glucose \< 7.78 mmol/L) with COVID-19 (39.4% vs. 16.8% respectively; unadjusted HR 2.20; 95% CI, 1.27--3.81; p = 0.005) at a mean observation of 17 days period [@b0070].

1.2. Outcomes in patients with new-onset hyperglycemia without diabetes versus diabetes (new-onset and or pre-existing diabetes) and COVID-19 {#s0015}
---------------------------------------------------------------------------------------------------------------------------------------------

Only few studies reported this outcome. Bode *et al.* [@b0045] showed a significant increase in death in patients with new-onset hyperglycemia without diabetes, compared to patients with pre-existing diabetes (41.7% vs. 14.8% respectively; p \< 0.001). In contrast, Zhang *et al.* [@b0050] demonstrated increased trend but no significant differences in composite outcomes (MV, ICU admission and death) between patients with new-onset hyperglycemia without diabetes (OR 2.10; 95% CI, 0.65--6.83; p = 0.22) and with diabetes (new-onset or pre-existing).

1.3. Outcomes in patients with new-onset diabetes versus normoglycemic COVID-19 {#s0020}
-------------------------------------------------------------------------------

New-onset diabetes has been increasingly being reported as a case series during the pandemic of COVID-19, sometime presenting with acute diabetic ketoacidosis [@b0075], [@b0080]. Several studies have recently reported the outcomes with new-onset diabetes compared with normoglycemic individuals with COVID-19. In a retrospective analysis of 166 patients Zhang *et al.* [@b0050] found new-onset diabetes (FBG ≥ 7.0 mmol/L twice or HbA1c ≥ 6.5%) in 16% of cases (26/166) of COVID-19 but did not report the outcomes separately of this group. Interestingly, no significant increase (OR 2.61; 95% CI, 0.86--7.88; p = 0.09) in composite outcomes risk (MV, ICU admission and death) was noted in group having diabetes (both new-onset and pre-existing) compared to the normoglycemic people with COVID-19. In contrast, Li *et al.* [@b0065] found 21% (94/453) patients had new-onset diabetes (FPG ≥ 7 mmol/L and/or HbA1c ≥ 6.5%) and reported a significant increase in all-cause death (HR 9.42; 95% CI, 2.18--40.7) in a multi-variable analysis at a mean follow-up of 30 days, compared to individuals with normoglycemia and COVID-19. Similarly, Wang *et al.* [@b0060] reported 29% cases (176/605) of new-onset diabetes (FBG ≥ 7.0 mmol/L) had significantly higher 28-day in-hospital complications (OR 3.99; 95% CI, 2.71--5.88) and all-cause death (HR 2.30; 95% CI, 1.49--3.55; p = 0.002), compared to normoglycemic COVID-19. In a retrospective study of all 69 patients with new-onset diabetes, Yang *et al.* [@b0085] found new-onset diabetes (FBG ≥ 7.0 mmol/L for two times) as an independent predictor for death (HR 3.75; 95% CI 1.26--11.15; p = 0.017) even after a multivariable analysis. KM survival analysis found a significantly (p = 0.002) higher mortality rate in new-onset diabetes with COVID-19. In a very recent study by Fadini *et al.* [@b0090] that analyzed 413 patients and had 5% cases (21/413) of new-onset diabetes (HbA1c ≥ 6.5% or a random glucose level ≥ 11.1 mmol/L (≥200 mg/dL) with symptoms of hyperglycemia), there was a significant increase (RR 3.06; 95% CI, 2.04--4.57) in severe COVID-19 (ICU admission and death) in people with new-onset diabetes, compared to normoglycemic individual.

1.4. Outcomes in patients with new-onset diabetes versus pre-existing diabetes {#s0025}
------------------------------------------------------------------------------

Two studies compared the outcomes between new-onset and pre-existing diabetes. Notably, Li *et al.* [@b0065] at a mean follow-up of 30 days reported nearly 2-fold higher risk of all-cause death in individuals with new-onset diabetes (HR 9.42; 95% CI, 2.18--40.7), in comparison to pre-existing diabetes (HR 4.63; 95% CI 1.02--21.0) vs. normoglycemic people with COVID-19. Coincidentally, Fadini *et al.* [@b0090] also found a stronger association in increase (p = 0.004) in ICU admission or death in people with new-onset diabetes (RR 3.06; 95% CI, 2.04--4.57), compared with pre-existing diabetes (RR 1.55, 95% C.I. 1.06--2.27) vs. normoglycemic patients with COVID-19, in unadjusted analysis. Even after the adjustment for age and sex, new-onset diabetes had a stronger association and a significant increase in ICU admission and death, compared to people with pre-existing diabetes.

In summary, these findings suggest -- a. Patients with new-onset hyperglycemia even without a frank diabetes due to any cause (Stress-induced/ COVID-19-induced/ pre-existing dysglycemia), are associated with a poorer outcome compared to the normoglycemic individuals as well as those with pre-existing diabetes and COVID-19. b. New-onset diabetes in patients with COVID-19 is associated with a significantly higher complications and all-cause death, compared to individuals with normoglycemia and pre-existing diabetes. [Table 1](#t0005){ref-type="table"} summarizes the outcomes from all the studies that studied new-onset hyperglycemia.Table 1Types of hyperglycemia and outcomes in patients with COVID-19.**First authorNNormo-glycemia (n)New-onset hyper-glycemia without diabetes (n)New-onset/Newly detected diabetes (n)Known diabetes (n)ResultsRemarksGroup 1Group 2Group 3AGroup 3B**Bode et al. [@b0045]1122671257^!^NA194A significant increase in mortality was observed in Group 2 and Group 3B compared with Group 1 (28.8% vs. 6.2% respectively; p \< 0.001). In addition, a significant increase in death was reported in Group 2 compared with Group 3B (41.7% vs. 14.8% respectively; p \< 0.001).Increased mortality in patients with hyperglycemia due to any cause, compared with normoglycemia. New-onset hyperglycemia without diabetes had even poorer outcome compared with pre-existing diabetes.Zhang et al. [@b0050]16684^\#^21^\#^26^\#^35^\#^Significant increase in composite outcomes risk (MV, admission in ICU and death) in Group 2 (OR 5.47; 95% CI, 1.51--19.82; p = 0.010) compared with group 1. No significant differences in composite outcomes (OR 2.61; 95% CI, 0.86--7.88; p = 0.09) in groups 3 (A + B) compared with group 1, and between group 2 (OR 2.10; 95% CI, 0.65--6.83, p = 0.22) and group 3 (A + B).Poorer outcomes in patients with hyperglycemia without diabetes compared with normoglycemic COVID-19.Sardu et al. [@b0055]59267^\^^NA26Risk-adjusted Cox regression analysis found a 71% relative increase in mortality (HR 0.29; 95% CI, 0.08--0.96; p = 0.04) from severe disease through 18 days in Group 2 and 3B, compared with Group 1.Both new-onset hyperglycemia without diabetes and pre-existing diabetes had poorer outcomes compared with normoglycemic patients with COVID-19Wang et al. [@b0060]605329100^\$^176^\$^NA28-day in-hospital complications were significantly higher in Group 3A (OR 3.99; 95% CI, 2.71--5.88) and Group 2 (OR 2.61; 95% CI, 1.64--4.41) compared with Group 1. All cause-death at 28-day after a multi-variable analysis in Group 3A was significantly higher (HR 2.30; 95% CI, 1.49--3.55; p = 0.002), compared to Group 1.Both new-onset diabetes and hyperglycemia without diabetes had poorer outcomes compared with normoglycemic COVID-19. New-onset diabetes had worst prognosis.Li et al. [@b0065]453132129\*94\*98\*At a mean follow up of 30 days, all-cause death was significantly higher in Group 3A (HR 9.42; 95% CI, 2.18--40.7), and Group 3B (HR 4.63; 95% CI 1.02--21.0) but only a trend in increase was observed in Group 2 (HR 3.29; 95% CI, 0.65--16.6), compared to Group 1 after the adjustment of age, sex, smoking, SBP and TC.Patients with new-onset diabetes had worst outcome compared with pre-existing diabetes and normoglycemic COVID-19.Coppelli et al. [@b0070]27114966^@^NA56^@^Mortality was significantly higher in Group 2 compared with Group 1 (39.4% vs. 16.8%; unadjusted HR 2.20; 95% CI, 1.27--3.81; p = 0.005) and only marginally higher in Group 3B compared to Group 1 (28.6% vs. 16.8%; unadjusted HR 1.73; 95% CI, 0.92--3.25; p = 0.09). Only hyperglycemia at admission (Group 2) remained an independent predictor of mortality (HR 1.80; 95% CI 1.03--3.15; p = 0.04) after the multiple adjustments.New-onset hyperglycemia without diabetes had poorer outcomes compared with normoglycemic COVID-19.Yang et al. [@b0085]69NANA69^\*\*^NAMultivariable analysis found Group 3A was an independent predictor for death (HR 3.75; 95% CI 1.26--11.15; p = 0.017). KM survival analysis found a significantly higher mortality rate in Group 3A (p = 0.002).New-onset diabetes has worst prognosis.Fadini et al. [@b0090]413306NA21^\#\#^86In unadjusted analysis, Group 3A showed a stronger association in increase (p = 0.004) in ICU admission or death (RR 3.06; 95% CI, 2.04--4.57) than Group 3B (RR 1.55, 95% C.I. 1.06--2.27) when compared with Group 1. Even after the adjustment for age and sex, Group 3A had strong association and a significant increase in ICU admission and death compared with Group 3B and Group 1. At each 2 mmol/L (36 mg/dl) increase in FPG at admission had a significantly (21% relative) increase in severity (RR 1.21; 95% CI, 1.11--1.32; p \< 0.001).Both new-onset diabetes and pre-existing diabetes has poorer outcomes compared with normoglycemic COVID-19. New-onset diabetes has even worser prognosis compared with pre-existing diabetes and normoglycemic COVID-19.FPG- fasting plasma glucose; KM- Kaplan-Meier; OR- odds ratio; HR -- hazard ratio; RR- risk ratio; MV- mechanical ventilation; ICU- intensive care unit; SBP- systolic blood pressure; TC- total cholesterol; ^!^ two or more blood glucoses \> 180 mg/dL occurred within any 24-hour period with an HbA1C \< 6.5% or no HbA1C testing done during hospitalization; ^\#^ Group 1: patients without a history of diabetes and FPG \< 7.0 mmol/L, Group 2: FPG ≥ 7.0 mmol/L (≥126 mg/dL) once and HbA1c \< 6.5%, Group 3A: FBG ≥ 7.0 mmol/L twice or HbA1c ≥ 6.5%, Group 3B: history of diabetes; ^\^^ at-admission hyperglycemia was defined if plasma glucose \> 7.77 mmol/l (\>140 mg/dL); ^\$^ Group 2: FBG 6.1--6.9 mmol/L, Group 3A: FBG ≥ 7.0 mmol/L; \* Group 1: FPG \< 5.6 mmol/L and HbA1c \< 5.7%, Group 2: FPG 5.6--6.9 mmol/L and/or HbA1c 5.7--6.4%, Group 3A: FPG ≥ 7 mmol/L and/or HbA1c ≥ 6.5%; ^@^ Group 1: at-admission blood glucose \< 7.78 mmol/L, Group 2: no diabetes and glucose ≥ 7.78 mmol/L at admission; ^\*\*^ FBG ≥ 7.0 mmol/L for two times during hospitalization and without a history of diabetes and corticosteroid intake; ^\#\#^ Group 3A: defined by a HbA1c ≥ 6.5% or a random glucose level ≥ 11.1 mmol/L (≥200 mg/dL) with signs and symptoms of hyperglycemia.
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